Defining the noninferiority margin and analysing noninferiority: an overview TA Althunian, A de Boer, RHH Groenwold, OH Klungel British journal of clinical pharmacology 83 (8), 1636-1642, 2017 | 156 | 2017 |
Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review TA Althunian, A de Boer, OH Klungel, WN Insani, RHH Groenwold Trials 18, 1-9, 2017 | 75 | 2017 |
Effectiveness of topical vancomycin in the prevention of spinal surgical site infections: a retrospective cohort study RT Tafish, AF Alkhaldi, A Bourghli, TA Althunian Antimicrobial Resistance & Infection Control 10, 1-8, 2021 | 10 | 2021 |
Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines OM Albalawi, MI Alomran, GM Alsagri, TA Althunian, TM Alshammari Saudi Pharmaceutical Journal 30 (2), 180-184, 2022 | 7 | 2022 |
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: a retrospective noninferiority cohort replication study TA Althunian, A de Boer, RHH Groenwold, KO Rengerink, PC Souverein, ... Pharmacoepidemiology and Drug Safety 29 (10), 1263-1272, 2020 | 6 | 2020 |
The impact of regulatory restrictions on pregabalin use in Saudi Arabia: an interrupted time series analysis TA Althunian, MI Alomran, GM Alsagri, MM Alrasheed, TM Alshammari Pharmacoepidemiology and Drug Safety 31 (5), 577-582, 2022 | 5 | 2022 |
Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate TA Althunian, A de Boer, RHH Groenwold, OH Klungel Journal of Clinical Epidemiology 104, 15-23, 2018 | 4 | 2018 |
Assessment of the regulatory dialogue between pharmaceutical companies and the European Medicines Agency on the choice of noninferiority margins TA Althunian, A de Boer, AK Mantel-Teeuwisse, RHH Groenwold, ... Clinical Therapeutics 42 (8), 1588-1594, 2020 | 3 | 2020 |
The association between drug pricing and drug shortage in Saudi Arabia: a retrospective database analysis MA Alowairdhi, FH Alhussain, MI Alomran, OA Almadani, ... Journal of Pharmaceutical Policy and Practice 16 (1), 91, 2023 | 1 | 2023 |
Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in … TAI Althunian, A De Boer, RHH Groenwold, KO Rengerink, PC Souverein, ... Pharmacoepidemiology and Drug Safety 28 (S2), 57-58, 2019 | 1 | 2019 |
Insights into regulatory and design Aspects of bioequivalence trials in Saudi Arabia: A comprehensive analysis T Althunian, B Alzenaidy, R Aroba, O Almadani, F Alqahtani, A Binajlan, ... Authorea Preprints, 2023 | | 2023 |
A large proportion of a Saudi population with type 2 diabetes mellitus was found to be non-adherent to antidiabetics: a retrospective cohort study T Althunian, OA Almadani, GM Alsagri, HA Badreldin, TM Alshammari Authorea Preprints, 2023 | | 2023 |
Drug shortage in Saudi Arabia was mostly common in drugs that are more expensive outside Saudi Arabia: A retrospective database analysis T Althunian, MA Alowairdhi, FH Alhussain, MI Alomran, OA Almadani, ... | | 2023 |
Recording type 2 diabetes mellitus in a standardised central Saudi database: a retrospective validation study TA Althunian, MM Alrasheed, FA Alnofal, RT Tafish, MA Mira, RA Alroba, ... BMJ open 13 (3), e065468, 2023 | | 2023 |
Real-World Analysis of the Safety and Effectiveness of Apixaban Therapy in Cancer Patients with Venous Thromboembolism in Saudi Arabia L Alabdelmuhsin, M Alwethairi, O Almadani, TA Althunian, HA Badreldin Journal of Vascular Diseases 2 (1), 102-111, 2023 | | 2023 |
The association between drug pricing and drug shortage: A retrospective database analysis M Alowairdhi, F Alhussain, M Alomran, O Almadani, N Alkhammash, ... | | 2023 |
Validating the standardized and ICD-9 code of type 2 diabetes mellitus in a Saudi common data model TAI Althunian, M Alrasheed, F Alnofal, R Tafish, MA Mira, RA Alroba, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 451-451, 2022 | | 2022 |
Oral Presentation: Analyzing the US Post-Marketing Safety Surveillance of COVID-19 Vaccines O Albalawi, M Alomran, G Alsagri, T Althunian, T Alshammari Drug Safety 44 (12), 1395-1396, 2021 | | 2021 |
The impact of regulatory restrictions on the use of pregabalin: An interrupted time-series TA Althunian, M Alomran, G Alsagri, M Alrasheed, TM Alshammari PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 360-360, 2021 | | 2021 |
Analyzing the US Post-marketing safety surveillance of COVID-19 vaccines (preprint) O Albalawi, M Alomran, G Alsagri, T Althunian, T Alshammari | | 2021 |